SCHEMBL3559414

SCHEMBL3559414

CCOc1cc(C(CC(N)=O)N2Cc3c(Cl)ccc(N)c3C2=O)ccc1OC

nearest known ligand 0.55

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 12/20 0.55
PDE4B Q07343 12/20 0.55
PDE4C Q08493 12/20 0.55
PDE4D Q08499 12/20 0.55
TNF P01375 6/20 0.50
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3557146 0.92 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DTNF
SCHEMBL3558305 0.91 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DTNF
SCHEMBL2964448 0.91 TNF (0.47) PDE4APDE4BPDE4CPDE4DTNF
SCHEMBL3557602 0.89 PDE4B (0.44) PDE4APDE4BPDE4CPDE4DTNF
SCHEMBL3395545 0.88 PDE4B (0.60) PDE4APDE4BPDE4CPDE4D
SCHEMBL3557228 0.88 PDE4B (0.60) PDE4APDE4BPDE4CPDE4D
SCHEMBL3563183 0.87 PDE4B (0.55) PDE4APDE4BPDE4CPDE4DTNF
Cyclopropane SCHEMBL15252438 0.86 PDE4B (0.52) PDE4APDE4BPDE4CPDE4DTNF
SCHEMBL8310216 0.84 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DTNF
SCHEMBL1378711 0.84 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DTNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1605896-B1 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2013-09-18 EP claimed
US-7799819-B2 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2010-09-21 US claimed
JP-2006519851-A 2006-08-31 JP claimed
US-7034052-B2 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2006-04-25 US claimed
EP-1605896-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-12-21 EP claimed
US-20040254214-A1 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-12-16 US claimed
WO-2004080423-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-09-23 WO claimed
EP-1605896-B1 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2013-09-18 EP disclosed
US-7799819-B2 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2010-09-21 US disclosed
US-20090131505-A1 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses MAN HON-WAH 2009-05-21 US disclosed
US-7511072-B2 7-amido-isoindolyl compounds and methods of its use CELGENE CORPORATION (US) 2009-03-31 US disclosed
US-20070254942-A1 7-amido-isoindolyl compounds and methods of its use CELGENE CORPORATION. 2007-11-01 US disclosed
US-7256210-B2 7-amido-isoindolyl compounds and methods of their use CELGENE CORPORATION (US) 2007-08-14 US disclosed
US-7034052-B2 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2006-04-25 US disclosed
US-20060058362-A1 7-Amido-isoindolyl compounds and methods of their use MAN HON-WAH 2006-03-16 US disclosed
EP-1605896-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-12-21 EP disclosed
US-20040254214-A1 7-Amido-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-12-16 US disclosed
WO-2004080423-A2 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058362-A1 7-Amido-isoindolyl compounds and methods of their use MCL1, APC, HPGDS PDE4A 1516/4885PDE4B 2106/4885PDE4C 1281/4885
US-20040254214-A1 7-Amido-isoindolyl compounds and their pharmaceutical uses MCL1, APC, THPO PDE4A 445/4885PDE4B 729/4885PDE4C 403/4885
US-20090131505-A1 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses THPO, MCL1, HPGDS PDE4A 576/4885PDE4B 564/4885PDE4C 874/4885
US-20070254942-A1 7-amido-isoindolyl compounds and methods of its use MCL1, THPO, APC PDE4A 2086/4885PDE4B 1964/4885PDE4C 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.